Vir Biotechnology will participate in the 4th HC Wainwright

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Philosophy, Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research PhD, participating in a virtual fireside Q&A at HC Wainwright 4th The annual Hepatitis B Virus (HBV) Conference will be held on Wednesday, October 25 at 7:00 am Pacific Time/10:00 am Eastern Time.

You can watch the live webcast of the fireside chat under Events and Presentations in the Investors section of the Vir website: It will be archived there for 30 days.

About Vir Biotechnology
Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious diseases. Vir has assembled two technology platforms designed to stimulate and enhance the immune system by leveraging key observations of natural immune processes. Its current clinical development pipeline includes product candidates targeting hepatitis B and D viruses, influenza A and B, human immunodeficiency virus and COVID-19. Vir is developing multiple preclinical drug candidates, including candidates targeting RSV/MPV and HPV. Vir frequently posts information on its website that may be important to investors.


Source link

Leave a Comment